Hongbo Pharmaceutical announced that on December 25, 2025, the initial price of the shareholder inquiry and transfer was 25.27 yuan/share, with 24 institutions effectively subscribed for 138.78 million shares, with an effective subscription ratio of 1.99 times; the proposed transfer of 6.9793 million shares have been fully subscribed, and 20 institutions were initially identified as transferees; the transfer was not carried out through centralized bidding transactions or bulk transactions, and the transferee cannot be transferred within 6 months after the transfer.

Hongbo Pharmaceutical announced that on December 25, 2025, the initial price of the shareholder inquiry and transfer was 25.27 yuan/share, with 24 institutions effectively subscribed for 138.78 million shares, with an effective subscription ratio of 1.99 times; the proposed transfer of 6.9793 million shares have been fully subscribed, and 20 institutions were initially identified as transferees; the transfer was not carried out through centralized bidding transactions or bulk transactions, and the transferee cannot be transferred within 6 months after the transfer.